ImmunoGen Undervalued In AbbVie Deal, Shareholder Claims

By Elaine Briseño · January 8, 2024, 4:57 PM EST

A shareholder alleges that ImmunoGen Inc. directors and advisers significantly undervalued the company while preparing to sell to AbbVie Inc., including by failing to consider the $1.6 billion in projected revenue...

To view the full article, register now.